Ziihera – Talk Bio

Actionable Insights Powered by AI

Zymeworks Pivots to Royalty-Driven Model After Strong Ziihera Data in Gastric Cancer

10 hours ago talkbio0Tagged Biological Factors, buyback, erbB-2 Receptor, Jazz, Malignant neoplasm of stomach, milestone payments, Regulatory Filing, Royalty-Driven Model, Strategy, Ziihera, Zymeworks

Zymeworks; royalty-driven model; Ziihera; gastric cancer; HER2; biologics; milestone payments; stock buyback; biotech strategy; Jazz Pharmaceuticals; regulatory filing